Phase I trial of concurrent sunitinib and radiation therapy as preoperative treatment for soft tissue sarcoma.

ABSTRACT:

Introduction

Although the introduction of multimodal treatment of soft tissue sarcoma improved local tumour control, local failure still occurs in a good number of patients. Therefore, further improvement of current treatment strategies is necessary. The proposed study treatment will combine standard external beam radiation and the orally administered receptor tyrosine kinase inhibitor sunitinib.

Methods and analysis

Patients with soft tissue sarcoma will receive sunitinib and irradiation as neoadjuvant treatment. Radiotherapy will be administered as intensity modulated radiation therapy with a total dose of 50.4 Gy in 28 fractions (5 1/2 weeks). Patients will receive sunitinib daily for 2 weeks prior to and then concurrently with irradiation. Sunitinib will be given in two

SUBMITTER: Jakob J 

PROVIDER: S-EPMC3780318 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature